Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22617482 | 1.00 | GAA (0.53) | GAAEPHX2ALDH1A1TDP1CES2 | |
| SCHEMBL31472623 | 0.87 | GAA (0.53) | GAAEPHX2ALDH1A1TDP1 | |
| SCHEMBL31472619 | 0.82 | GAA (0.52) | GAAEPHX2ALDH1A1TDP1 | |
| SCHEMBL31472635 | 0.82 | GAA (0.52) | GAAEPHX2ALDH1A1TDP1 | |
| SCHEMBL31472633 | 0.82 | GAA (0.52) | GAAEPHX2ALDH1A1TDP1 | |
| SCHEMBL31472630 | 0.82 | GAA (0.54) | GAAEPHX2ALDH1A1TDP1 | |
| SCHEMBL31472622 | 0.82 | GAA (0.54) | GAAEPHX2ALDH1A1TDP1 | |
| SCHEMBL31472627 | 0.79 | EPHX2 (0.50) | GAAEPHX2ALDH1A1 | |
| SCHEMBL31472628 | 0.79 | EPHX2 (0.50) | GAAEPHX2ALDH1A1 | |
| SCHEMBL22617503 | 0.77 | CES2 (0.48) | CES2CES1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | GAA 2054/4885EPHX2 3920/4885ALDH1A1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.